CVS Health Financials

CVS Health Corp

CVSNYSE

Trade with Public

$96.74

-0.46-0.47%

가까이에: Sep 4, 5:00 PM EST

$96.34

-0.40-0.42%

시간외: Sep 4, 7:15 PM EST

개요 뉴스 실적 전망 이벤트 목표가재무심리 지분 현황 배당금 비교 옵션 주식 보고서

CVS Health Financials

CVS Health (CVS) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

Eli Lilly's Weight-Loss Empire Keeps Expanding As Mounjaro, Zepbound Generate Nearly $15 Billion

Eli Lilly (LLY) beat Q2 earnings expectations & raised 2026 guidance as Mounjaro and Zepbound drove $22.97B in revenue. Read more.

Vandana Singh

CVS Targets Affordable GLP-1 Access With New Eli Lilly Deal

CVS Health beats Q2 earnings expectations and hikes FY26 guidance, but shares fall on profit-taking. Get the full financial breakdown.

Vandana Singh

PRO
CORRECTION: CVS Health Raises FY2026 Adj EPS Guidance from $7.30-$7.50 to $7.90-$8.10 vs $7.45 Est; FY2026 Revenue expected to be more than $414.000B vs $409.235B Est

Benzinga Newsdesk

PRO
CVS Health Raises FY2026 GAAP EPS Guidance from $6.24-$6.44 to $6.84-$7.04 vs $6.12 Est

CVS Health (NYSE:CVS) raises FY2026 GAAP EPS guidance from $6.24-$6.44 to $6.84-$7.04 vs $6.12 analyst estimate..

Benzinga Newsdesk

PRO
CVS Health Q2 Adj. EPS $2.58 Beats $1.85 Estimate, Sales $106.096B Beat $100.114B Estimate

Benzinga Newsdesk

These Analysts Increase Their Forecasts On CVS Health After Strong Q1 Results

CVS Health (NYSE:CVS) reported upbeat Q1 earnings & raised 2026 guidance. Analysts have positive outlook with price targets raised.

Avi Kapoor

CVS Health Corp

CVS Health Financials

Earnings & Guidance News

Eli Lilly's Weight-Loss Empire Keeps Expanding As Mounjaro, Zepbound Generate Nearly $15 Billion

CVS Targets Affordable GLP-1 Access With New Eli Lilly Deal

PRO
CORRECTION: CVS Health Raises FY2026 Adj EPS Guidance from $7.30-$7.50 to $7.90-$8.10 vs $7.45 Est; FY2026 Revenue expected to be more than $414.000B vs $409.235B Est

PRO
CVS Health Raises FY2026 GAAP EPS Guidance from $6.24-$6.44 to $6.84-$7.04 vs $6.12 Est

PRO
CVS Health Q2 Adj. EPS $2.58 Beats $1.85 Estimate, Sales $106.096B Beat $100.114B Estimate

These Analysts Increase Their Forecasts On CVS Health After Strong Q1 Results

뉴스

파트너 / 기고자

벤징가 글로벌

Benzinga

Benzinga

Benzinga

CVS Health Corp

CVS Health Financials

Earnings & Guidance News

Eli Lilly's Weight-Loss Empire Keeps Expanding As Mounjaro, Zepbound Generate Nearly $15 Billion

CVS Targets Affordable GLP-1 Access With New Eli Lilly Deal

PROCORRECTION: CVS Health Raises FY2026 Adj EPS Guidance from $7.30-$7.50 to $7.90-$8.10 vs $7.45 Est; FY2026 Revenue expected to be more than $414.000B vs $409.235B Est

PROCVS Health Raises FY2026 GAAP EPS Guidance from $6.24-$6.44 to $6.84-$7.04 vs $6.12 Est

PROCVS Health Q2 Adj. EPS $2.58 Beats $1.85 Estimate, Sales $106.096B Beat $100.114B Estimate

These Analysts Increase Their Forecasts On CVS Health After Strong Q1 Results

Benzinga

뉴스

파트너 / 기고자

벤징가 글로벌

PRO
CORRECTION: CVS Health Raises FY2026 Adj EPS Guidance from $7.30-$7.50 to $7.90-$8.10 vs $7.45 Est; FY2026 Revenue expected to be more than $414.000B vs $409.235B Est

PRO
CVS Health Raises FY2026 GAAP EPS Guidance from $6.24-$6.44 to $6.84-$7.04 vs $6.12 Est

PRO
CVS Health Q2 Adj. EPS $2.58 Beats $1.85 Estimate, Sales $106.096B Beat $100.114B Estimate